The selling of olestra

Research output: Contribution to journalArticle

Abstract

PROCTER AND GAMBLE Company spent 30 years and an estimated $500 million to bring its non-digestible fat substitute, olestra, to market. The Food and Drug Administration approved olestra as a food additive but requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function. In obtaining approval for olestra, P and G conducted a lengthy, persistent, and comprehensive campaign to enlist support from members of Congress; FDA staff; and food, nutrition, and health professionals. This campaign raises larger questions about corporate influence on government policies, and the relationships of corporations to health professionals. To address these larger concerns, the author reviews the history of olestra's approval; describes P and G's campaign to obtain support from FDA and Congress, to defend olestra against critics, and to market it to professionals, the press, and consumers; and suggests implications for public health policies.

Original languageEnglish (US)
Pages (from-to)508-520
Number of pages13
JournalPublic Health Reports
Volume113
Issue number6
StatePublished - 1998

Fingerprint

Fat Substitutes
Food Additives
Health
United States Food and Drug Administration
Public Policy
Health Policy
sucrose polyester
Public Health
History
Food

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

The selling of olestra. / Nestle, M.

In: Public Health Reports, Vol. 113, No. 6, 1998, p. 508-520.

Research output: Contribution to journalArticle

Nestle, M 1998, 'The selling of olestra', Public Health Reports, vol. 113, no. 6, pp. 508-520.
Nestle, M. / The selling of olestra. In: Public Health Reports. 1998 ; Vol. 113, No. 6. pp. 508-520.
@article{40fe8c5dfbd3425ab01af0f19a993daf,
title = "The selling of olestra",
abstract = "PROCTER AND GAMBLE Company spent 30 years and an estimated $500 million to bring its non-digestible fat substitute, olestra, to market. The Food and Drug Administration approved olestra as a food additive but requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function. In obtaining approval for olestra, P and G conducted a lengthy, persistent, and comprehensive campaign to enlist support from members of Congress; FDA staff; and food, nutrition, and health professionals. This campaign raises larger questions about corporate influence on government policies, and the relationships of corporations to health professionals. To address these larger concerns, the author reviews the history of olestra's approval; describes P and G's campaign to obtain support from FDA and Congress, to defend olestra against critics, and to market it to professionals, the press, and consumers; and suggests implications for public health policies.",
author = "M. Nestle",
year = "1998",
language = "English (US)",
volume = "113",
pages = "508--520",
journal = "Public Health Reports",
issn = "0033-3549",
publisher = "Association of Schools of Public Health",
number = "6",

}

TY - JOUR

T1 - The selling of olestra

AU - Nestle, M.

PY - 1998

Y1 - 1998

N2 - PROCTER AND GAMBLE Company spent 30 years and an estimated $500 million to bring its non-digestible fat substitute, olestra, to market. The Food and Drug Administration approved olestra as a food additive but requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function. In obtaining approval for olestra, P and G conducted a lengthy, persistent, and comprehensive campaign to enlist support from members of Congress; FDA staff; and food, nutrition, and health professionals. This campaign raises larger questions about corporate influence on government policies, and the relationships of corporations to health professionals. To address these larger concerns, the author reviews the history of olestra's approval; describes P and G's campaign to obtain support from FDA and Congress, to defend olestra against critics, and to market it to professionals, the press, and consumers; and suggests implications for public health policies.

AB - PROCTER AND GAMBLE Company spent 30 years and an estimated $500 million to bring its non-digestible fat substitute, olestra, to market. The Food and Drug Administration approved olestra as a food additive but requires products containing olestra to carry a warning statement about its potential effects on gastrointestinal function. In obtaining approval for olestra, P and G conducted a lengthy, persistent, and comprehensive campaign to enlist support from members of Congress; FDA staff; and food, nutrition, and health professionals. This campaign raises larger questions about corporate influence on government policies, and the relationships of corporations to health professionals. To address these larger concerns, the author reviews the history of olestra's approval; describes P and G's campaign to obtain support from FDA and Congress, to defend olestra against critics, and to market it to professionals, the press, and consumers; and suggests implications for public health policies.

UR - http://www.scopus.com/inward/record.url?scp=0032407015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032407015&partnerID=8YFLogxK

M3 - Article

C2 - 9847922

AN - SCOPUS:0032407015

VL - 113

SP - 508

EP - 520

JO - Public Health Reports

JF - Public Health Reports

SN - 0033-3549

IS - 6

ER -